PharmaSGP reduces IPO size because of market volatility

The IPO of PharmaSGP, the German manufacture of natural drugs and medicines, was a smaller affair than had been originally envisaged by the sellers, after the return of equity market volatility meant that the deal had to be priced at the bottom of the range.